Articles by Claude Camire

About Claude Camire

Claude Camiré has been involved in Biotech, Healthcare and Pharma industries for almost 40 years, completing over $1 billion in financings and M&A transactions, and participated in licensing of drugs for biopharma companies. For more than a decade, he worked as a corporate finance advisor and research analyst at Dundee Securities and Paradigm Capital, initiating coverage on over 30 Canadian companies. For three decades, he worked for companies such as Abbott Labs, Biochem Pharma, Prometic Life Sciences, and Sanofi.

Food Quarterly – Who Decides What’s For Dinner Tonight?

November 29, 2021 Claude Camire

We review different companies that compose the industry: the trends, issues, challenges, and their strategies. For this first edition, we will just provide an overview of the key points. Our ultimate goal is to identify companies and products that may have a strategic advantage in competing in this transforming industry.
[more]

Potential New Treatment Option for Hospitalized COVID-19 Patients that are Diagnosed with Acute Kidney Injury

May 26, 2021 Claude Camire

Patients hospitalized by COVID-19 that end up in intensive care are likely to be diagnosed with acute kidney injury (AKI), face few treatment options and a high mortality rate, but a new potential option is on the way. [more]

XORTX Update – Announces Results from COVID-19 Study and Receives Positive Feedback from FDA for XRx-101

November 27, 2020 Claude Camire

XORTX is a biopharmaceutical company focused on developing drugs that could reduce serum acid uric levels. An Initiation Equity Research Report on XORTX was published by eResearch on August 16, 2020. [more]

XORTX Breaking Up the Code with Uric Acid

August 16, 2020 Claude Camire

New 33-page Initiation Equity Research Report on XORTX, with a Speculative Buy rating and one-year price target of $2.30/share. The Company has two potential late stage drugs in development focused on kidney diseases that could initiate pivotal Phase 3 clinical trials in the next 12 months. [more]